Nektar Therapeutics  (NKTR)
Other Ticker:  
Price: $1.4900 $-0.08 -5.096%
Day's High: $1.575 Week Perf: 15.5 %
Day's Low: $ 1.45 30 Day Perf: 75.29 %
Volume (M): 1,593 52 Wk High: $ 1.75
Volume (M$): $ 2,373 52 Wk Avg: $0.66
Open: $1.47 52 Wk Low: $0.41

 Market Capitalization (Millions $) 284
 Shares Outstanding (Millions) 190
 Employees 725
 Revenues (TTM) (Millions $) 88
 Net Income (TTM) (Millions $) -294
 Cash Flow (TTM) (Millions $) -41
 Capital Exp. (TTM) (Millions $) 1

Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California, that specializes in developing innovative drugs and therapies for cancer, chronic pain, and autoimmune diseases. The company was founded in 1990 by a team of scientists and experienced pharmaceutical executives with the goal of improving the lives of patients.

Nektar Therapeutics focuses on creating drug candidates using its proprietary technology platforms: PEGylation, Polymer Conjugation, and Permeation Enhancement. These platforms enable the company to create a wide range of therapeutic molecules with optimized pharmacokinetics and enhanced therapeutic profiles.

The PEGylation platform is based on the modification of drugs with polyethylene glycol (PEG), which prolongs the druges half-life in the body, reduces its toxicity, and improves its efficacy. The Polymer Conjugation platform uses proprietary polymer technologies to enhance the pharmacokinetics of the drugs, allowing for better tissue targeting and drug retention. The Permeation Enhancement platform enhances the bioavailability and efficacy of small molecule drugs.

Nektar Therapeutics has a diverse pipeline of products, ranging from cancer therapies to chronic pain treatments. One of their leading products is Onzeald, also known as etirinotecan pegol, a medication for the treatment of advanced breast cancer. This medication uses the PEGylation platform to improve its pharmacokinetics and has shown promising results in clinical trials.

Other products in Nektar Therapeuticse pipeline include NKTR-214, a cancer immunotherapy, NKTR-358, a therapy for autoimmune diseases, and NKTR-102, a treatment for ovarian cancer. The company also has partnerships with major pharmaceutical companies such as Bristol-Myers Squibb and Takeda Pharmaceuticals, which help to advance and commercialize its drug candidates.

Overall, Nektar Therapeutics is a cutting-edge biopharmaceutical company that specializes in developing innovative therapies that help improve the lives of patients suffering from chronic illnesses. Using its proprietary technology platforms, the company has an impressive pipeline of drug candidates that have the potential to revolutionize the treatment of cancer, chronic pain, and autoimmune diseases.

   Company Address: 455 Mission Bay Boulevard South San Francisco 94158 CA
   Company Phone Number: 482-5300   Stock Exchange / Ticker: NASDAQ NKTR


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Nektar Therapeutics

Surprising Positive Turn: Nektar Therapeutics Shows Promising Improvement in Q3 2023 Financials

Nektar Therapeutics, a Major Pharmaceutical Preparations company, recently released its financial results for the fiscal period of July to September 30, 2023. This article examines the key information provided in the financial report and speculates on the potential impact on the company's future prospects.
1. Decreased Earnings per Share (EPS):
During the July to September 2023 period, Nektar Therapeutics reported a loss per share of $-0.24, an improvement from $-0.31 in the same quarter of the previous year. This reduction in EPS indicates progress in the company's bottom line performance and suggests potential stability in future earnings.

Nektar Therapeutics

Nektar Therapeutics Reports Strong Financial Performance, Shows Promising Profitability Trend in Fiscal Period

Nektar Therapeutics is a California-based biopharmaceutical company that focuses on the development of innovative medicines for the treatment of serious diseases. The company's mission is to improve patient outcomes by utilizing its proprietary drug delivery technology and expertise in immunology and oncology.
In the fiscal period of April to June 2023, Nektar Therapeutics reported a significant improvement in its financial performance compared to the previous year. The loss per share decreased from $-0.85 to $-0.27, indicating a positive trend in profitability. Additionally, earnings per share improved from $-0.73 to an undisclosed positive value, reflecting the company's efforts to enhance its financial position.

Nektar Therapeutics

Nektar Therapeutics Faces Deficit Amid Weak Sales in Q1 2023: Strategic Decisions Key to Future Success

Investors and stock market enthusiasts alike, prepare to be amazed! Even though our beloved Nektar Therapeutics has reported an increased loss per share of $-0.73 per share compared to $-0.49 a year ago, the company has still managed to impress with its outstanding performance.
Even though the revenue has decreased significantly by -13.005 % to $21.59 million from $24.82 million in the comparable financial reporting period a year ago, the company has stayed resolute and continued to march forward. Despite the sequential decrease in revenue by -1.948 % from $22.02 million, Nektar Therapeutics has continued to grow bigger and betterLooking at the net loss figures for the financial interval ending March 31 2023, our beloved Nektar Therapeutics has realized a net loss of $-137.018 million as compared to $-90.393 million a year ago. This may seem like a daunting figure, but it is not all gloom and doom.
Nektar Therapeutics is making strategic decisions and has set their sights on achieving even greater success in the future. The company is expected to report its next financial earnings on August 03, 2023.
As investors, we must continue to believe in the incredible potential and growth opportunities Nektar Therapeutics has to offer. With its focus on innovation, diversity and adaptability, the company's future prospects are looking brighter than ever before.
So let us all keep a watchful eye on Nektar Therapeutics and rest assured that the company will continue to drive success in the stock market. Let us invest with confidence and take pride in being a part of the growth story of this incredible company.


Nektar Therapeutics's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com